Xencor (NASDAQ:XNCR) Share Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Xencor, Inc. (NASDAQ:XNCR)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $13.02 and traded as low as $11.90. Xencor shares last traded at $12.20, with a volume of 871,476 shares.

Analysts Set New Price Targets

XNCR has been the subject of a number of recent analyst reports. Barclays raised their price objective on Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. Zacks Research downgraded Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Wall Street Zen downgraded Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, JPMorgan Chase & Co. raised their price objective on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Monday, May 11th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $24.50.

Xencor Trading Down 0.1%

The business has a fifty day moving average of $12.10 and a 200 day moving average of $13.02. The company has a market capitalization of $904.51 million, a PE ratio of -5.33 and a beta of 0.92.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The firm had revenue of $4.52 million for the quarter, compared to analysts’ expectations of $27.86 million. During the same quarter last year, the business earned ($0.66) earnings per share. The business’s revenue was down 86.2% compared to the same quarter last year. Equities analysts forecast that Xencor, Inc. will post -3.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Xencor

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jefferies Financial Group Inc. boosted its stake in shares of Xencor by 620.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock valued at $11,030,000 after buying an additional 620,440 shares during the period. Primecap Management Co. CA boosted its stake in shares of Xencor by 1.4% in the 3rd quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock valued at $125,218,000 after buying an additional 147,700 shares during the period. Baker BROS. Advisors LP boosted its stake in shares of Xencor by 64.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,102,106 shares of the biopharmaceutical company’s stock valued at $12,928,000 after buying an additional 431,675 shares during the period. Vanguard Group Inc. boosted its stake in shares of Xencor by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock valued at $109,703,000 after buying an additional 61,692 shares during the period. Finally, Erste Asset Management GmbH boosted its stake in shares of Xencor by 26.3% in the 4th quarter. Erste Asset Management GmbH now owns 480,200 shares of the biopharmaceutical company’s stock valued at $7,347,000 after buying an additional 100,000 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.